Literature DB >> 11418463

Genetically modified bone marrow continuously supplies anti-inflammatory cells and suppresses renal injury in mouse Goodpasture syndrome.

T Yokoo1, T Ohashi, Y Utsunomiya, J S Shen, Y Hisada, Y Eto, T Kawamura, T Hosoya.   

Abstract

In chronic inflammation, macrophages and neutrophils, which are derived from bone marrow, play a pivotal role. Therefore, reconstitution of bone marrow with anti-inflammatory stem cells may modify inflammation. In this study, transplantation-based gene therapy was applied to glomerular inflammation for a long-lasting suppression of the glomerular damage seen in chronic nephritis. Bone marrow cells were harvested from male donor mice, which had received 5-fluorouracil 3 days previously, and transduced with an interleukin 1 (IL-1) receptor antagonist (IL-1Ra) or a mock gene using a retrovirus vector. After confirmation that transduced cells possessed the transgene at approximately 0.7 copies per cell and secreted recombinant IL-1Ra, these cells were infused into sublethally irradiated (6 Gy) female recipients once daily for 4 consecutive days. These female recipient mice had the male Y antigen in bone marrow, liver, and spleen, and 10% to 20% of their spleen cells possessed the transgene even 8 weeks after transplantation. Glomerulonephritis was then induced in these mice. Renal function and histology were retarded in the mice whose bone marrow was reconstituted with IL-1Ra-producing cells compared with mock transduced cells. In situ hybridization using a Y painting probe revealed that transplanted donor cells were recruited into the glomerulus upon induction of nephritis, suggesting therapeutic effects were channeled through the secretion of IL-1Ra from these cells. Furthermore, the survival rate after a second challenge with nephrotoxic antibody was significantly improved in the IL-1Ra chimera. These results suggest that reconstitution of bone marrow for continuous supply of anti-inflammatory cells may be a useful strategy for the treatment of chronic inflammation.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11418463     DOI: 10.1182/blood.v98.1.57

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  6 in total

Review 1.  Gene therapy targeting kidney diseases: routes and vehicles.

Authors:  Yoshitaka Isaka
Journal:  Clin Exp Nephrol       Date:  2006-12-20       Impact factor: 2.801

Review 2.  Leukocytes in glomerular injury.

Authors:  Stephen R Holdsworth; Peter G Tipping
Journal:  Semin Immunopathol       Date:  2007-10-16       Impact factor: 9.623

3.  Human mesenchymal stem cells in rodent whole-embryo culture are reprogrammed to contribute to kidney tissues.

Authors:  Takashi Yokoo; Toya Ohashi; Jin Song Shen; Ken Sakurai; Yoichi Miyazaki; Yasunori Utsunomiya; Masanori Takahashi; Yoshio Terada; Yoshikatsu Eto; Tetsuya Kawamura; Noriko Osumi; Tatsuo Hosoya
Journal:  Proc Natl Acad Sci U S A       Date:  2005-02-22       Impact factor: 11.205

4.  Essential role of Gas6 for glomerular injury in nephrotoxic nephritis.

Authors:  Motoko Yanagita; Yoshikazu Ishimoto; Hidenori Arai; Kojiro Nagai; Tsuyoshi Ito; Toru Nakano; David J Salant; Atsushi Fukatsu; Toshio Doi; Toru Kita
Journal:  J Clin Invest       Date:  2002-07       Impact factor: 14.808

5.  Application of regenerative medicine for kidney diseases.

Authors:  Takashi Yokoo; Akira Fukui; Eiji Kobayashi
Journal:  Organogenesis       Date:  2007-01       Impact factor: 2.500

6.  Irradiation prolongs survival of Alport mice.

Authors:  Kan Katayama; Mitsuo Kawano; Ichiro Naito; Hitoshi Ishikawa; Yoshikazu Sado; Nagisa Asakawa; Tomohiro Murata; Kazuki Oosugi; Michiyo Kiyohara; Eiji Ishikawa; Masaaki Ito; Shinsuke Nomura
Journal:  J Am Soc Nephrol       Date:  2008-05-14       Impact factor: 10.121

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.